U.S. regulators have expanded approval for Pfizer's COVID-19 vaccine,for people aged 12 to 15.
The FDA expanded emergency authorization after reviewing clinical data, which showed the vaccine's efficacy to be 100 percent, and that it is well tolerated.
The decision makes Pfizer's vaccine the first in the U.S. to be authorized for younger teens and adolescents.
The vaccine had previously been authorized for people aged 16 and older.
Pfizer is also planning to seek approval for children between 2 and 11 years old in September.
Its vaccine safety and efficacy study in children ages 6 months to 11 years old is ongoing.